Pharmacotherapy of cardiac arrhythmias in acute myocardial infarction.
D000109:Acetylcholine / Q000627:therapeutic use; D000200:Action Potentials; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D001949:Bretylium Compounds / Q000627:therapeutic use; D004071:Digitalis Glycosides / Q000627:therapeutic use; D006321:Heart / Q000503:physiopathology; D006801:Humans; D008012:Lidocaine / Q000627:therapeutic use; D008564:Membrane Potentials; D009203:Myocardial Infarction / Q000150:complications; D010672:Phenytoin / Q000627:therapeutic use; D011342:Procainamide / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D001949:Bretylium Compounds; D004071:Digitalis Glycosides; D010672:Phenytoin; D008012:Lidocaine; D011802:Quinidine; D011342:Procainamide; D000109:Acetylcholine